World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
79
Citations
23771
World Ranking
1677
National Ranking
826

Medicine

D-Index
80
Citations
24273
World Ranking
17081
National Ranking
8560

Larry W. Kwak publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Larry W. Kwak sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 456 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Larry W. Kwak D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Larry W. Kwak sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 79 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2020 - Fellow of the Indian National Academy of Engineering (INAE)

Overview

Larry W. Kwak is affiliated with the City Of Hope National Medical Center in the United States. Their primary research focus is within the field of Medicine, with significant contributions across subfields such as Oncology, Pathology and Forensic Medicine, Immunology, Molecular Biology, and Genetics.

The scientist's work includes extensive research on CAR-T cell therapy, lymphoma diagnosis and treatment, and chronic lymphocytic leukemia. Additional research topics covered include monoclonal and polyclonal antibodies, immunotherapy and immune responses, immune cell function and interaction, and cancer immunotherapy and biomarkers.

Frequent publication venues for their work are as follows:

  • Blood
  • Blood Advances
  • The Lancet Haematology
  • Molecular Therapy
  • Clinical Lymphoma Myeloma & Leukemia

Notable recent papers authored or coauthored include:

  • Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE, 2022, Blood
  • The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma, 2020, Cancer Immunology Research
  • Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP, 2021, Clinical Cancer Research
  • Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade, 2023, Blood
  • CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia, 2022, Leukemia

Collaborators who frequently coauthor with Larry W. Kwak include:

  • Stephen J. Forman
  • Alex F. Herrera
  • Steven T. Rosen
  • Leslie Popplewell
  • Matthew Mei

In 2020, Larry W. Kwak was recognized as a Fellow of the Indian National Academy of Engineering (INAE).

Best Publications

  • Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2

    Arya Biragyn;Pier Adelchi Ruffini;Cynthia A. Leifer;Elena Klyushnenkova

  • Mammalian defensins in immunity: more than just microbicidal.

    De Yang;Arya Biragyn;Larry W Kwak;Joost J Oppenheim

  • Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.

    Maurizio Bendandi;Christopher D. Gocke;Carol B. Kobrin;Floyd A. Benko

  • Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors

    Larry W. Kwak;Michael J. Campbell;Debra K. Czerwinski;Sarah Hart

  • Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

    Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad

  • Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial

    Frank J. Hsu;Clemens B. Caspar;Debra Czerwinski;Larry W. Kwak

  • Roles of antimicrobial peptides such as defensins in innate and adaptive immunity

    J J Oppenheim;A Biragyn;L W Kwak;D Yang

  • Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.

    L W Kwak;J Halpern;R A Olshen;S J Horning

  • Detection of Tumor Messenger RNA in the Serum of Patients with Malignant Melanoma

    Michael S. Kopreski;Floyd A. Benko;Larry W. Kwak;Christopher D. Gocke

  • Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

    Yasuhiro Oki;Mansoor Noorani;Pei Lin;Richard E. Davis

  • Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

    Issa F Khouri;Peter McLaughlin;Rima M Saliba;Chitra Hosing

  • Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens

    Arya Biragyn;Munhsuren Surenhu;De Yang;Pier Adelchi Ruffini

  • Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

    Arya Biragyn;Kenji Tani;Michael C. Grimm;Steven Weeks

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

    Larry W. Kwak;Howard A. Young;Robin W. Pennington;Steve D. Weeks

  • Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

    Young Hee Lee;Natalia Martin-Orozco;Natalia Martin-Orozco;Peilin Zheng;Jing Li

  • Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

    L.W. Kwak;P.L. Duffey;C.W. Reynolds;D.L. Longo

  • Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

    Yuhong Zhou;Yuhong Zhou;Haijun Wang;Wenjing Fang;Jorge E. Romaguer

  • Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

    Jorge E. Romaguera;Luis E. Fayad;Lei Feng;Kimberly Hartig

  • Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

    Nathan H Fowler;R Eric Davis;Seema Rawal;Loretta Nastoupil

Frequent Co-Authors

Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Qing Yi
Qing Yi Houston Methodist
Stephen J. Forman
Stephen J. Forman City Of Hope National Medical Center
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Steven T. Rosen
Steven T. Rosen City Of Hope National Medical Center
Arya Biragyn
Arya Biragyn National Institutes of Health
Jatin P. Shah
Jatin P. Shah Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related healthcare degrees can open diverse career opportunities. Nursing professionals, for example, may explore specialized roles such as Psychiatric-Mental Health Nurse Practitioners through affordable PMHNP programs. These programs provide flexibility and cost-effective education options for advancing clinical skills.

Another path involves becoming a Doctor of Nursing Practice (DNP). Understanding how much does a DNP make can help prospective students assess the return on investment for advanced degrees, as DNP graduates often access higher salary ranges and leadership roles in healthcare.

Registered nurses aiming to expand their scope can consider acute care NP certification. This additional credential is essential for those who want to transition from primary care to acute care settings, offering specialized training to manage critically ill patients effectively.

For faster entry into nurse practitioner roles, accelerated FNP programs offer an efficient pathway by condensing coursework for qualified candidates. Researching best accelerated nurse practitioner online programs helps prospective students find reputable and fast-tracked education options.

Exploring these related degrees and certifications can enhance career growth while complementing a background in immunology. Each pathway provides unique skills and credentials applicable across healthcare environments.

Best Scientists Citing Larry W. Kwak

Trending Scientists

Recently Published Articles